Le Lézard
Classified in: Business

MMOF GP II, LLC Distributes Shares to Members


LOS ANGELES, Nov. 22, 2019 /CNW/ - MMOF GP II, LLC (the "Securityholder"), located at 5880 Jefferson Blvd, Suite G, Los Angeles, CA 90016, announces that it completed today, in accordance with its constating documents, an in-kind distribution to the members of the Securityholder of 7,694,380 Class B Common Shares ("Class B Shares") of MM Can USA, Inc. ("PC Corp"), a subsidiary of MedMen Enterprises Inc. (the "Issuer"), which is located at 10115 Jefferson Blvd, Culver City, CA 90232.

Pursuant to the articles of incorporation of PC Corp and the Support Agreement dated as of May 28, 2018 between the Issuer, PC Corp and MM Enterprises USA, LLC, and subject to the terms and conditions thereof, such distributed Class B Shares (the "Distributed Shares") may be redeemed from time to time by the holders thereof for cash or an equivalent number of Class B Subordinate Voting Shares (the "Subordinate Voting Shares") of the Issuer, with the form of such redemption consideration being at the option of PC Corp.

The Distributed Shares represent ownership and control of approximately 3.19% of the Issuer's issued and outstanding Subordinate Voting Shares on a partially-diluted basis and approximately 1.12% on a fully-diluted basis. The Securityholder is the general partner of MedMen Opportunity Fund II, LP ("Fund II"). The Securityholder no longer holds any Class B Shares.

All of the Distributed Shares are subject to, and notwithstanding their distribution to the members of the Securityholder continue to be subject to, a lock-up agreement entered into by Fund II with PC Corp, pursuant which they are not permitted to be sold, transferred or otherwise disposed of until November 25, 2019, at which time, the restrictions on resale pursuant to such agreement will be immediately lifted as to one-twelfth of the Distributed Shares and thereafter in increments over an 11-month period as to the remaining Distributed Shares.

The distribution by the Securityholder to its members of the Distributed Shares was made in connection with the ongoing operations of the Securityholder.

This press release is issued pursuant to National Instrument 62-103 ? The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which requires a report to be filed on SEDAR (www.sedar.com) containing additional information with respect to the foregoing matters. A copy of this report may be obtained by contacting medmen@standishmanagement.com.

SOURCE MMOF GP II, LLC


These press releases may also interest you

at 03:30
Decathlon, a pioneer in applying RFID technology, has taken an early lead among global retailers in adopting intelligent automation solutions Geek+ systems have been deployed in seven phases on Decathlon sites, with two new sites set up remotely at...

at 03:05
transcosmos inc. has opened a new business location in Kuala Lumpur, the second branch office of TRANSCOSMOS (MALAYSIA) SDN BHD (Headquarters: Kuala Lumpur, Malaysia; transcosmos Malaysia), a company established in 2014, in order to accommodate the...

at 03:00
Billhighway, the leading financial management platform serving component-based organizations, is proud to announce the launch of a new integration with ePly, an innovative conference management software company. The collaborative solution provides...

at 03:00
Swiss Post Solutions (SPS), a leading outsourcing provider for business process solutions and innovative services in document management, announced today that it is partnering with Lehigh University to provide campus mail services. Located in...

at 03:00
HashCash Consultants is extending its blockchain expertise through scalable solutions and services specifically designed to bring reformation within the real estate sector. The USA based company's blockchain solutions for real estate aims to address...

at 02:47
Lipidor AB today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to commence in Q1 2021...



News published on 22 november 2019 at 18:22 and distributed by: